Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Open access
Sanz, Miguel A., Montesinos, Pau, Rayón, Chelo, Holowiecka, Alexandra, de la Serna, Javier, Milone, Gustavo, de Lisa, Elena, Brunet, Salut, Rubio, Vicente, Ribera, José M., Rivas, Concha, Krsnik, Isabel, Bergua, Juan, González, José, Díaz-Mediavilla, Joaquín, Rojas, Rafael, Manso, Félix, Ossenkoppele, Gert, González, José D., Lowenberg, Bob·2010·Blood

Abstract

A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (PETHEMA LPA99 trial) has demonstrated a high antileukemic efficacy in acute promyelocytic leukemia. We designed a new trial (LPA2005) with the objective of achieving stepwise improvements in outcome. Between July 2005 and April 2009, low- and intermediate-risk patients (leukocytes < 10 × 109/L) received a reduced dose of mitoxantrone for the second consolidation course, whereas high- risk patients younger than 60 years of age received cytarabine combined with ATRA and idarubicin in the first and third consolidation courses. Of 372 patients attaining complete remission after ATRA plus idarubicin (92.5%), 368 proceeded to consolidation therapy. For low- and intermediate-risk patients, duration of neutropenia and thrombocytopenia and hospital stay were significantly reduced without sacrificing antileukemic efficacy, compared with the previous LPA99 trial. For high-risk patients, the 3-year relapse rate was significantly lower in the LPA2005 trial (11%) than in the LPA99 (26%; P = .03). Overall disease-free survival was also better in the LPA2005 trial (P = .04). In conclusion, the lower dose of mitoxantrone resulted in a significant reduction of toxicity and hospital stay while maintaining the antileukemic activity, and the combination of ATRA, idarubicin, and cytarabine for high-risk acute promyelocytic leukemia significantly reduced the relapse rate in this setting. Registered at http://www.clinicaltrials.gov as NCT00408278.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-01-266007

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 328

Metadata

Authors
Sanz, M. A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., de Lisa, E., Brunet, S., Rubio, V., Ribera, J. M., Rivas, C., Krsnik, I., Bergua, J., González, J., Díaz-Mediavilla, J., Rojas, R., Manso, F., Ossenkoppele, G., González, J. D., & Lowenberg, B.
Venue
Blood
Published
2010-06-24
Volume
115
Issue
25
Pages
5137-5146
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2084219839
Cited by
328
References
18
FWCI
10.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. https://app.cochat.ai/papers/10.1182/blood-2010-01-266007
The paper
Sanz, M. A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., de Lisa, E., Brunet, S., Rubio, V., Ribera, J. M., Rivas, C., Krsnik, I., Bergua, J., González, J., Díaz-Mediavilla, J., Rojas, R., Manso, F., Ossenkoppele, G., González, J. D., & Lowenberg, B. (2010). Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. https://doi.org/10.1182/blood-2010-01-266007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.